A Tapered-pulsed Fidaxomicin Regimen Following Treatment in Patients With Multiple Clostridioides difficile Infection Recurrences

Clin Infect Dis. 2021 Sep 15;73(6):1107-1109. doi: 10.1093/cid/ciab233.

Abstract

We treated 46 patients with multiple recurrent Clostridioides difficile infections (mrCDI) using a tapered-pulsed (T-P) fidaxomicin regimen, the majority of whom failed prior T-P vancomycin treatment. Sustained clinical response rates at 30 and 90 days were 74% (34/46) and 61% (28/46). T-P fidaxomicin shows promise for management of mrCDI.

Keywords: Clostridioides difficile; Oral Vancomycin; fidaxomicin; recurrent C. difficile infection.

Publication types

  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Anti-Bacterial Agents / therapeutic use
  • Clostridioides
  • Clostridioides difficile*
  • Clostridium Infections* / drug therapy
  • Fidaxomicin
  • Humans
  • Recurrence

Substances

  • Anti-Bacterial Agents
  • Fidaxomicin